Feedback / Questions
ifenprodil (NP-120) - Seyltx
https://www.globenewswire.com/news-release/2024/03/27/2853408/0/en/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-U-S-Based-Seyltx-for-USD-2M-and-a-20-Equity-Position.html
Mar 28, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next